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Impaired degradation of glycosaminoglycans (GAGs) with consequent intralysosomal accumulation of undegraded products
causes a group of lysosomal storage disorders known asmucopolysaccharidoses (MPSs). Characteristically, MPSs are recognized by
increased excretion in urine of partially degraded GAGs which ultimately result in progressive cell, tissue, and organ dysfunction.
There are eleven diﬀerent enzymes involved in the stepwise degradation of GAGs. Deficiencies in each of those enzymes result
in seven diﬀerent MPSs, all sharing a series of clinical features, though in variable degrees. Usually MPS are characterized by a
chronic and progressive course, with diﬀerent degrees of severity. Typical symptoms include organomegaly, dysostosis multiplex,
and coarse facies. Central nervous system, hearing, vision, and cardiovascular function may also be aﬀected. Here, we provide
an overview of the molecular basis, enzymatic defects, clinical manifestations, and diagnosis of each MPS, focusing also on the
available animal models and describing potential perspectives of therapy for each one.
1. Introduction
Themucopolysaccharidoses (MPSs) are a group of lysosomal
storage disorders caused by deficiency of enzymes catalyzing
the stepwise degradation of glycosaminoglycans (GAGs) and
characterized by intralysosomal accumulation and increased
excretion in urine of partially degraded GAGs, which
ultimately results in cell, tissue, and organ dysfunction [1].
Glycosaminoglycans (previously called mucopolysaccha-
rides), with the exception of hyaluronic acid, are the degrada-
tion products of proteoglycans that exist in the extracellular
matrix and are proteolytic cleaved, giving origin to GAGs,
which enter the lysosome for intracellular digestion. There
are four diﬀerent pathways of lysosomal degradation of
GAGs, depending on the molecule to be degraded: dermatan
sulfate, heparan sulfate, keratan sulfate, and chondroitin
sulfate. The stepwise degradation of glycosaminoglycans
requires 10 diﬀerent enzymes: four glycosidases, five sulfa-
tases, and one nonhydrolytic transferase, whose structure,
biosynthesis, processing, and cDNA sequence have already
been extensively documented. Deficiencies of each one of
these enzymes have already been reported and result in
seven diﬀerent MPSs, all of them sharing a series of clinical
features, even though in variable degrees (summarized in
Table 1) [1, 2].
Usually, MPSs are characterized by a chronic and
progressive course, with diﬀerent velocities of progression
depending on the severity of each one. The typical symptoms
include organomegaly, dysostosis multiplex, and a charac-
teristic abnormal facies. Hearing, vision, and cardiovascular
function may also be aﬀected. Additionally, joint mobility
may also be compromised. The majority of symptoms may
be explained by abnormal accumulation of undegraded
substrates within the lysosomes. In fact, the continued
presentation of GAGs to cell for degradation results in
storage, which gives rise to an enlargement of lysosomes.
As substrates accumulate, the lysosomes swell and occupy
more and more of the cytoplasm. As a consequence of
this increased number and size of lysosomes, other cellular
organelles may be obscured, and the nuclear outline may
be deformed. As the process continues, the enlarged cells
lead to organomegally. Abnormalities observed in heart cells
and function may also be explained by GAGs accumulation.
The increase of storage material within the cells of the heart
valves causes an alteration of the cell’s outline, changing
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them from fusiform to round. As a consequence, the valve
leaflet and cordae tendinea become thickener and interfere
with normal cardiac function, producing valvular stenosis.
At corneal level, also, storage of undegraded GAGs results in
reflection and refraction of light, leading to the cloudiness
which is so typical of these pathologies. Also at the CNS
level, swollen neurons and lysosomes may produce lesions
that include the development of meganeurites and neurite
sprouting (reviewed in [3, 4]).
Traditionally, MPSs are recognized through analysis
of urinary GAGs. Several methods have been devised, to
precise qualitative identification and quantitative measure-
ments. These analyses of urinary GAGs allow discrimination
between broad classes of MPSs but cannot distinguish
subgroups. Definitive diagnosis is usually accessed through
enzymatic assays of the defective enzyme in cultured fibrob-
lasts, leukocytes, and serum or plasma (reviewed in [1]).
During the last decade; however, dried blood spot technology
was also introduced for enzymatic assays, allowing cheaper,
easier, feasible diagnosis and opening the possibility for large
population screenings (see Section 11 for more details).
In general, MPSs are transmitted in an autosomal
recessive fashion, except for MPS II, which is X-linked.
This paper provides an overview of the molecular basis,
enzymatic defects, clinical manifestations, and diagnosis
of each glycosaminoglycan storage disease, focusing also
on the respective animal models and describing potential
perspectives of therapy which are being tested as well as the
ones which are already available (summarized in Table 2).
2. Mucopolysaccharidosis I
Mucopolysaccharidosis I is caused by a deficiency of α-
L-iduronidase (IDUA; EC 3.2.1.76) and can result in a
wide range of phenotypic involvement with three major
recognized clinical entities: Hurler (MPS IH; MIM#607014),
Hurler-Scheie (MPS IH/S; MIM#607015), and Scheie (MPS
IS) syndromes. Hurler and Scheie syndromes represent
phenotypes at the severe and mild ends of the MPS I clinical
spectrum; respectively, and the Hurler-Scheie syndrome is
intermediate in phenotypic expression [20]. It is important
to stress that, although MPS I may be subdivided into these
three clinically diverse entities, the underlying enzymatic
defect is common to all of them, being all caused bymutation
in the gene encoding α-L-iduronidase (IDUA).
Functionally, α-L-iduronidase is essential to the correct
metabolism of both dermatan sulfate and of heparan sulfate,
hydrolyzing the terminal α-L-iduronic acid residues of the
above-referred glycosaminoglycans [1].
In 1992, Scott and colleagues [21] were able to clone and
purify the gene that encodes this enzyme, IDUA, demonstrat-
ing that it spans approximately 19 kb and contains 14 exons.
The first 2 exons are separated by an intron of 566 bp, a large
intron of approximately 13 kb follows, and the last 12 exons
are clustered within 4.5 kb. Previously, this gene was mapped
to 4p16.3, through unequivocal in situ hybridization and
southern blot analysis of mouse-human cell hybrids [22].
There are, presently, several animal models known for
MPS I.
In 1979, Haskins and colleagues [5] described α-L-
iduronidase deficiency in a cat, and, few years later, Shull et
al. [6] and Spellacy et al. [23] reported a similar deficiency
in the dog. Subsequent studies lead to cloning and charac-
terization of the canine IDUA gene as well as the mutation
causing the observed phenotype [24, 25] and proved it to
be a good model for study of human MPS I. So, in 1994,
Shull and collaborators [26] published the first results of
enzyme replacement therapy in the canine model. Through
intravenous administration of recombinant human α-L-
iduronidase, these authors managed to obtain a remarkable
resolution of lysosomal storage in both hepatocytes and
Kupﬀer’s cells. In the same year, Grosson et al. [27] mapped
the homologous IDUA locus in the mouse to chromosome 5.
That knowledge was later used to create a knock-out mouse
presenting the characteristic MPS I features [7, 28].
Currently, both hematopoietic stem cell transplantation
(HSCT) and enzyme replacement therapy (ERT) using
laronidase (recombinant human α-L-iduronidase, Aldu-
razyme) are available for MPS I. HSCT is the recommended
treatment for patients with severe MPS I, before 2 years
of age [29–32]. ERT is recommended for the other cases,
and it has been shown to be eﬀective in ameliorating
some of the clinical manifestations of MPS disease. Among
positive eﬀects are decreased hepatosplenomegaly, improved
respiratory and myocardial function and physical capacity
[33–35] as well as improvement in active movement followed
by enhanced self-care [36]. Recently, several reports have
been published trying to evaluate long-term eﬀect of ERT on
the natural history of treated patients. From those studies,
several conclusions have been reached. Concerning treated
patients’ growth pattern, it became clear that children with
MPS I grow considerably slower than healthy individu-
als, and diﬀerences between healthy and aﬀected children
increase with age [37]. Other relevant evidences show that
early treatment of attenuated MPS I may significantly delay
or prevent the onset of the major clinical signs, substantially
modifying the natural history of the disease [38]. Additional
investigation is needed to clarify the mechanisms by which
improvements are achieved in laronidase-treated patients.
Such knowledge may support the development of ERT
directly targeting the brain.
2.1. Hurler’s Syndrome (MPS IH). Hurler’s syndrome is the
most severe form of MPS I and has been, over the last
decades, the prototype description of MPS. Nevertheless,
this may be misleading, since not all MPSs share the same
features, and this pathology in particular is not representative
of all of them, but only of the most severe end of a
broad clinical spectrum (reviewed in [1]). Like all other
MPSs, the clinical course of this disease is progressive, with
multiple organ and tissue involvement. Hallmark clinical
features of Hurler syndrome include coarse facies, corneal
clouding, mental retardation, hernias, dysostosis multiplex,
and hepatosplenomegaly. Children with Hurler’s syndrome
appear normal at birth and develop the characteristic
appearance over the first years of life [39]. Length is often
normal until about 2 years of age when growth stops; by age
of 3 years, height is under the third percentile [40]. Cardiac
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Table 2: Available therapeutic approaches for mucopolysaccharidoses.
Pathology Subtype Available therapeutic approaches
MPS I
Hurler (H) HSCT (recommended before 2 years of age)
Hurler -Scheie (H/S) ERT with Aldurazyme (laronidase; recombinant human α-L-iduronidase)
Scheie (S) ERT with Aldurazyme (laronidase; recombinant human α-L-iduronidase)
MPS II Hunter ERT with Elaprase (idursulfase; recombinant human iduronate sulfatase)
MPS III
Sanfilippo A ∗Not available∗
Sanfilippo B ∗Not available∗
Sanfilippo C ∗Not available∗
Sanfilippo D ∗Not available∗
MPS IV
Morquio A ERT: ongoing clinical trial (with recombinant human GALNS)
Morquio B ∗Not available∗
MPS VI (Maroteaux-Lamy) ERT with Naglazyme (galsulfase; recombinant human arylsulfatase B)
MPS VII (Sly) ∗Not available∗
MPS IX ∗Not available∗
disease and respiratory complications are common. Acute
cardiomyopathy associated with endocardial fibroelastosis
has been a presenting condition in some infants with MPS
I less than 1 year of age [41]. Upper and lower respiratory
tract infections are also frequent [42]. Developmental delay
is often apparent by 12 to 24months of age, with a maximum
functional age of 2 to 4 years followed by progressive
deterioration. Most children develop limited language as a
consequence of developmental delay, chronic hearing loss,
and enlarged tongue [1]. Dermal melanocytosis may also be
found in Hurler patients [43], as well as in patients suﬀering
from other LSDs, such as GM1 gangliosidosis. Nevertheless,
Hurler’s syndrome is the most common lysosomal storage
disease associated with dermal melanocytosis, as revealed by
a literature analysis.
2.2. Hurler-Scheie’s Syndrome (MPS IH/S). MPS IH/S corre-
sponds to a clinical phenotype which is intermediate between
the Hurler and the Scheie syndromes. It is characterized by
progressive somatic involvement with dysostosis multiplex
but little or no mental retardation. First symptoms usually
occur between 3 and 8 years. Characteristic features of
Hurler’s syndrome, such as corneal clouding, joint stiﬀness,
deafness, and valvular heart disease, can also appear in MPS
IH/S patients. Nevertheless, the onset of these symptoms
occurs much later than that in the severe MPS I type, begin-
ning in the midteens and leading to significant impairment
and loss of function. Other clinical features, such as microg-
nathism, pachymeningitis cervicalis, and compression of the
cervical cord due to GAG accumulation in the dura, may also
occur. Cardiac and respiratory complications may explain
the high clinical mortality (reviewed in [1]).
2.3. Scheie’s Syndrome (MPS IS). Scheie’s syndrome was
earlier thought to be a separate entity designated MPS V,
instead of a phenotypical subtype of MPS I [44]. This
pathology is characterized by a mild phenotype in which
dysostosis multiplex can be present. Joint involvement is
marked in the hand with a claw-hand deformity. Patients
also have genu valgum, stiﬀ, painful feet, and pes cavus [1].
Cardiac and respiratory complications are much milder than
in the Hurler syndrome, with aortic and mitral valvular
disease being a common feature [45]. At a respiratory
level, Perks et al. [46] have reported two brothers with
Scheie’s syndrome suﬀering from sleep apnea, but no
other complications are known. Intelligence is normal [1].
Pachymeningitis cervicalis (compression of the cervical cord
secondary to glycosaminoglycan accumulation in the dura)
may also occur.
3. Mucopolysaccharidosis II
(Hunter’s Syndrome)
Mucopolysaccharidosis II is the sole MPS transmitted in an
X-linkedmanner and is caused by deficiency of the lysosomal
enzyme iduronate sulfatase, which is crucial to the correct
degradation of heparan and dermatan sulfate, by cleaving
their O-linked sulfate. As a result, there is a progressive
accumulation of glycosaminoglycans in nearly all cell types,
tissues, and organs. Patients with MPS II excrete excessive
amounts of dermatan sulfate and heparan sulfate in the urine
[20, 47]. Hunter syndrome is caused by mutation in the gene
encoding iduronate-2-sulfatase (IDS).
Although the disease is known since the early 1970s,
being the first MPS to be defined clinically in humans, it
was not until the 1990s that the IDS was cloned. In 1991,
Wilson et al. [48] localized the gene to Xq28. Two years later,
Flomen and coworkers [49] described the gene’s structure as
containing 9 exons and characterized the intron sequences
surrounding them. In the same year, Wilson et al. [50]
reported the complete sequence of the IDS gene, which spans
approximately 24 kb. The potential promoter for IDS lacks a
TATA box but contains GC box consensus sequences, which
are consistent with its role as a housekeeping gene.
Curiously, a second IDS gene (IDS2) was identified by
Bondeson et al. [51]. It is a pseudogene and is located within
90 kb telomeric region of the IDS gene and involved in a
recombination event with the primary IDS gene in about
13% of patients with the Hunter syndrome.
Biochemistry Research International 5
Traditionally, the Hunter syndrome comprises 2 recog-
nized clinical entities, according to the severity of symptoms:
mild and severe. Although largely used, this nomenclature
does have its diﬃculties, since the mild and severe forms
represent the two ends of a wide and continuous spectrum of
clinical severity. Also, in terms of iduronate deficiency, these
forms cannot be distinguished since the enzyme’s activity is
equally deficient in both (reviewed in [1]). They are, though,
separated almost exclusively on clinical grounds, although
nowadays mutation analysis may help distinguish them.
This classification of MPS goes back to 1972, when
McKusick distinguished between the severe form (which he
called MPS IIA), with progressive mental retardation and
physical disability and death before age 15 years in most
cases, and the mild form (called MPS IIB) compatible with
survival to adulthood and in which intellect is impaired
minimally, if at all. He also pointed out the lack of corneal
clouding in the X-linked form of MPS as opposed to the
autosomal forms.
Presently, this classification has become obsolete since, in
2008,Wraith et al. [47] stated that MPS II should be regarded
as a continuum between the two extremes (severe and
attenuated). They noted that, although the clinical course for
the more severely aﬀected patients is relatively predictable,
there is considerable variability in the clinical phenotype and
progression of the more attenuated form of the disease and,
so, it would not be correct to consider the milder form as
a separate entity but, instead, look at Hunter’s disease as
a phenotypical continuum, with several possible degrees of
severity.
In 1998, Wilkerson et al. [8] described Hunter’s syn-
drome in a Labrador retriever, with the typical clinical
features observed in humans: coarse facies, macrodactyly,
corneal dystrophy, progressive CNS deterioration, and pos-
itive biochemical diagnosis for MPS through urine analysis.
After the successful results obtained in improving certain
disease manifestations in patients with MPS I, including
visceral manifestations and attenuation of neurologic disease
progression [29, 52], hematopoietic stem cells transplanta-
tion (HSCT) has also been performed in several patients
with MPS II. Unfortunately, although the transplantation of
hematopoietic stem cells provides some enzymatic recon-
struction in many target tissues with decreased excretion of
GAGs in urine, decreased liver and spleen volumes, dimin-
ished facial coarsening, and improved respiratory function
and joint mobility [53, 54], the results at neurological level
were disappointing (reviewed in [55]). The additional risk
of morbidity and mortality associated to this procedure
led investigators to focus their attention in ERT for this
pathology, with much better results, as discussed below.
A knock-out mouse model for MPS II was developed
by replacing exon 4 and a portion of exon 5 of IDS with
the neomycin-resistance gene [9, 56]. Aﬀected mice exhibit
a phenotype with notorious similarities to human disease,
both at the biochemical and the clinical levels [9]. Several
studies with this knock-out mouse model were done to
assess the eﬀect of ERT [56] as well as dose and various
dosing regimens of idursulfase in urine and tissue GAG levels
[57]. The results of these studies were quite promising, with
a marked decrease in urinary GAGs as well as decreased
GAG accumulation in several tissues [56] verified for several
idursulfase doses and several dosing frequencies [57]. These
studies have been used to support the first clinical trial
of recombinant IDS in Hunter’s syndrome patients. At the
moment, both phase I/II [58] and phase II/III [59] clinical
studies have proven not only the eﬃcacy but also the safety
of idursulfase replacement therapy. Consequently, ERT with
recombinant human iduronate sulfatase (Elaprase, idursul-
fase, Shire Human Genetic Therapies Inc.) was approved
in the US (July, 2006) and the European Union (January,
2007) for the treatment and the management of MPS II. The
recommended dose is 0.5mg/kg administered once weekly
as an intravenous infusion (reviewed in [55]). As time goes
by, additional evidence on the eﬃcacy of ERT for MPS
II patients is being published, as long-term treatments are
successful. This is the case of a recently published report on
the improvements observed in a 7 years and 10 months old
child who began a 36 months’ treatment with Elaprase at 4
years and 10 months. At the end of the treatment, the child
presented normal excretion of GAGs in urine, normal-sized
liver and spleen, and significant bone remodeling. Cardiac
and neurological development, however, still progressively
deteriorated [60]. This year, protective eﬀects of ERT in
MPS II patients were also reported for DNA damaging in
leukocytes [61] and oxidative stress [62].
4. Mucopolysaccharidosis III
(Sanfilippo’s Syndrome)
The Sanfilippo syndrome, or mucopolysaccharidosis III, is
caused by impaired degradation of heparan sulfate [1] and
includes 4 subtypes, each due to the deficiency of a diﬀerent
enzyme: heparan N-sulfatase (type A; MIM no. 252900),
α-N-acetylglucosaminidase (type B; MIM no. 252920),
acetyl CoA: α-glucosaminide acetyltransferase (type C; MIM
no. 252930), and N-acetylglucosamine-6-sulfatase (type D;
MIM#252940). At a clinical level, the four subtypes are quite
similar, with a characteristic severe central nervous system
degeneration associated with mild somatic disease. Onset of
clinical features usually occurs between 2 and 6 years, severe
neurologic degeneration occurs in most patients between 6
and 10 years of age, and death occurs typically during the
second or third decade of life. Type A has been reported to
be the most severe, with earlier onset and rapid progression
of symptoms and shorter survival [63].
4.1. Mucopolysaccharidosis IIIA (Sanfilippo A). General MPS
IIIA clinical features include severe mental retardation with
relatively mild somatic features (moderately severe claw hand
and visceromegaly, little or no corneal clouding, little or no
vertebral change). Usually, this pathology is characterized
by marked overactivity, destructive tendencies, and other
behavioral aberrations.
MPS IIIA phenotype is caused by mutations in the gene
encoding N-sulfoglucosamine sulfohydrolase, also named
heparan sulfate sulfatase (SGSH; 605270). This enzyme is
specific for sulfate groups linked to the amino group of
glucosamine.
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In 1995, the gene encoding N-sulfoglucosamine sul-
fohydrolase, SGSH, was isolated, sequenced, and cloned
[64]. Later, it was shown to contain 8 exons spanning
approximately 11 kb [65].
There are two animal models known for MPS IIIA.
The first to be discovered was the canine model when
Fischer et al. [10] identified sulfaminidase deficiency in
two adult wire-haired dachshund littermates. Subsequently,
Aronovich et al. [66] determined the normal sequence of the
canine heparan sulfate sulfatase gene and cDNA, through
PCR-based approaches. Another model was described in
2001, when Bhattacharyya and collaborators [11] found a
spontaneous mouse mutant of MPS IIIA resulting from a
missense mutation (D31N) in the murine sulfatase gene.
Aﬀected mice die at about 10 months of age, exhibiting
notorious visceromegaly, distended lysosomes and heparan
sulfate accumulation in urine. Hemsley and Hopwood
[67] found that these mice had severe brain involvement,
with impaired open field locomotor activity and behavioral
changes, suggesting axonal degeneration. Later, Settembre et
al. [68] observed increased autophagosomes resulting from
autophagosome-lysosome function in these mice. Similar
findings were observed in another mouse model of another
lysosomal storage disorder (multiple sulfatase deficiency;
MSD; MIM no. 272200), reinforcing the recent idea that
these diseases are disorders of autophagy, which may be
a common mechanism for neurodegenerative lysosomal
storage disorders.
MPS IIIA mice were recently tested for substrate depri-
vation therapy with both genistein and rhodamine B, two
chemicals that inhibit GAG synthesis ([4, 69], reviewed
in [70]). Encouraging results were obtained with both
compounds, and this therapeutic approach started to be
considered for severalMPSs (see Section 11 formore details).
Other interesting results were also obtained when siRNAs
were used to reduce GAG synthesis in MPS IIIA mice. Last
year, this approach was tested by Dziedzic et al. [71], who
managed to reduce mRNA levels of four genes, XYLT1,
XYLT2, GALTI, and GALTII, whose products are involved in
GAG synthesis. This decrease of levels of transcripts corre-
sponded to a decrease in levels of proteins encoded by them.
Moreover, eﬃciency of GAG production in these fibroblasts
was considerably reduced after treatment of the cells with
siRNA. Either way, substrate deprivation therapy seems to be
a promising approach for Sanfilippo’s syndrome type A.
Gene therapy approaches are also being tested in MPS
IIIA mice. Recently, promising results have been reported by
Fraldi et al. [72], who performed experiments with intrac-
erebral adeno-associated-virus- (AAV-) mediated delivery of
SGSH gene, together with SMUF1 gene, which exhibits an
enhancing eﬀect on sulfatase activity when coexpressed with
sulfatases. They observed a visible reduction in lysosomal
storage and inflammatory markers in transduced brain
regions, together with an improvement in both motor and
cognitive functions.
4.2. Mucopolysaccharidosis IIIB (Sanfilippo B). With a phe-
notype quite similar to MPS IIIA, the Sanfilippo syn-
drome B is characterized by deficiencies of α-N-acetyl-
glucosaminidase, caused by mutations in the NAGLU gene
that encodes this enzyme. α-N-Acetylglucosaminidase is
required for the removal of the N-acetylglucosamine residues
that exist in heparan sulfate or are generated during lysoso-
mal degradation of this polymer by the action of heparan
acetyl-CoA: α-glucosaminide N-acetyltransferase (reviewed
in [1]).
The NAGLU gene was cloned in 1995 by Zhao and
colleagues [73]. The deduced 743-amino acid protein has a
20- to 23-residue leader sequence, consistent with a signal
peptide, and 6 potential N-glycosylation sites. It contains 6
exons and spans 8.3 kb on chromosome 17q21 [74].
Similarly to the above-referred MPS III syndrome, there
is also a natural occurring mutant for Sanfilippo B. It
was described by Ellinwood and coworkers, in 2003, in
Schipperke’s dogs [12].
During the last decade, Li et al. [75] created a laboratorial
murine MPS IIIB was also constructed trough targeted
disruption of the NAGLU gene [76]. With a phenotype
quite similar to that of patients with MPS IIIB, this model
began immediately to be used for therapeutic approaches
as well as for pathogenesis studies. The first studies were
done to evaluate the potential of ERT for this pathology
[76]. The results, however, were quite disappointing since the
recombinant NAGLU produced in Chinese hamster ovary
(CHO) cells was not eﬃciently captured by MPS IIIB cells,
either in vitro [77, 78] or in vivo [76]. This diﬃculty has
turned the search for a treatment for MPS IIIB even more
challenging. Presently, several therapies are under evaluation
for this disease, including cell-mediated therapy, enzyme
enhancement therapy, substrate deprivation therapy, and
viral gene therapy (reviewed in [79]).
Promising results are being achieved through gene
therapy approaches inMPS IIIBmice, namely, through direct
microinjection into the brain of adeno-associated virus
(AAV) vectors coding for NAGLU [80–82] and intravenous
injections and intracranial gene delivery of lentiviral (LV)
vector of NAGLU [83–85].
4.3. Mucopolysaccharidosis IIIC (Sanfilippo C). Sanfilippo
syndrome C is, in general, characterized by the same clinical
features described to MPS IIIA. Nevertheless, the enzyme
deficiency in this pathology is diﬀerent from the one causing
the latter. Type C disease is caused by mutations in the
gene encoding heparan acetyl-CoA: α-glucosaminide N-
acetyltransferase (HGSNAT; 610453). This is the only known
lysosomal enzyme that is not a hydrolase. It catalyzes
the acetylation of the glucosamine amino groups that
have become exposed by the action of heparan-N-sulfatase
(reviewed in [1]).
TheHGSNAT gene was cloned in parallel by two diﬀerent
groups, during the last decade: Fan et al. [86] and Hrˇebı´cˇek
et al. [87]. The molecular defects underlying MPS IIIC
remained unknown for almost three decades due to the low
tissue content and the instability of HGSNAT [88].
To date, 54 HGSNAT sequence variants have been
identified including 13 splice-site mutations, 11 insertions
and deletions with consequent frameshifts and premature
termination of translation, 8 nonsense, and 18 missense
(reviewed in [89]).
Biochemistry Research International 7
Recently, two independent studies from Feldhammer et
al. [88] and Fedele and Hopwood [90] have performed
exhaustive functional analysis of the majority of the missense
mutations already reported for the HGSNAT gene. Attention
was focused in this particular type of mutations since
there are several MPS IIIC patients carrying only missense
mutations, either homozygous or heterozygous, who present
an unexpected severe phenotype. In fact, although splicing
and frameshift mutations are usually associated to that type
of phenotype, since they give rise to premature termina-
tion codons and trigger nonsense-mediated mRNA decay
(NMD); missense mutations are traditionally associated to
milder disease. Nevertheless, this typical/general pattern is
not observed forMPS IIIC. That is why these alterations were
specifically cloned, expressed, and analyzed for their folding,
targeting, and enzymatic activities. As a result, Fedele and
Hopwood [90] have observed that the expression levels and
enzymatic activity of most mutants were extremely low or
even negligible. Feldhammer and colleagues [88], on the
other hand, have observed that those mutations cause a
misfolding of the enzyme, which is not correctly glycosylated.
As a consequence, HGSNAT is not targeted to the lysosome
but, instead, stays in the endoplasmic reticulum (ER). Thus,
enzyme folding defects due to missense mutations, together
with NMD seem to be the major molecular mechanisms
underlyingMPS IIIC. This makesMPS IIIC a good candidate
for enzyme enhancement therapy, where active site-specific
inhibitors are used as pharmacological chaperones to modify
the conformation of the mutant lysosomal enzymes usually
retained and degraded in the ER, in order to increase the
level of the residual activity to a point which is suﬃcient to
reverse the clinical phenotypes [88]. Together with inhibitors
of heparan sulphate synthesis, pharmacological chaperones
are currently being tested to reduce storage of this polymer
in the CNS to levels suﬃcient to stop neuronal death and
reverse inflammation.
4.4. Mucopolysaccharidosis IIID (Sanfilippo D). Like the
previousMPS III subtypes, Sanfilippo’s syndrome D presents
a phenotype similar to MPS IIIA, with a singular enzyme
deficiency underlying it: mutation in the gene encoding N-
acetylglucosamine-6-sulfatase (GNS; 607664). The enzyme
was originally described as specific for the 6-sulphated N-
acetylglucosamine residues of heparan sulphate. However,
the early data have been reinterpreted, and given that this
sulfatase is in fact able to desulphate the 6-sulphated N-
acetylglucosamine present in α- or in β-linkage or even as
a free monosaccharide (reviewed in [1]).
N-Acetylglucosamine-6-sulfatase (EC 3.1.6.14) was puri-
fied and characterized by Freeman et al. [91], who identified
4 diﬀerent forms of the enzyme in liver. Its catalytic proper-
ties were studied by Freeman andHopwood [92]. Afterwards,
Robertson et al. [93] assigned the glucosamine-6-sulfatase
gene, which they symbolized G6S, to chromosome 12q14 by
in situ hybridization of a tritium-labeled G6S cDNA probe.
The localization was confirmed by using the cDNA clone in
analyses of DNA from human/mouse hybrid cell lines. More
recently, that information was completed by the work ofMok
et al. [94], who amplified and sequenced the promoter and
14 exons of the GNS gene from a patient with MPS IIID.
By analyzing that patient, it was also possible to identify
a homozygous nonsense mutation in exon 9, predicted to
result in premature termination at codon 355, as well as
two common synonymous coding SNPs. At the same time,
another group identified a 1-bp deletion in the GNS gene in
another aﬀected individual [95].
A naturally occurring large animal model was described
by Thompson et al. [13], who reported type D Sanfilippo’s
syndrome in a Nubian goat. Later, caprine MPS IIID was
used to evaluate the eﬃcacy of ERT in this pathology.
Recombinant caprine N-acetylglucosamine-6-sulfatase was
administered intravenously to one MPS IIID goat at 2, 3,
and 4 weeks of age. As a result, a marked reduction of
lysosomal storage vacuoles was observed in hepatic cells, but
no amelioration was noticed concerning the CNS lesions.
No residual enzyme activity was observed either in brain
or liver. Taking this preliminary results into account, it was
considered that other treatment regimens will be necessary
for MPS IIID [96].
5. Mucopolysaccharidosis IV
Mucopolysaccharidosis IV, or Morquio’s syndrome, is caused
by impaired degradation of keratan sulphate. Presently,
there are two known enzyme deficiencies causing 2 dif-
ferent subtypes of Morquio’s syndrome: deficiency in N-
acetylglucosamine-6-sulfatase (causing Morquio’s disease
type A; MIM no. 253000) and deficiency in β-galactosidase
(causing Morquio’s disease type B; MIM no. 253010). Both
MPS IV subtypes present a wide spectrum of clinical
manifestations, but there are some characteristic com-
mon features: short trunk dwarfism, fine corneal deposits,
spondyloepiphyseal dysplasia. Actually, the predominant
clinical features of Morquio’s syndrome are the ones related
to the skeleton. Most of the times, this severe somatic disease
is accompanied by a normal intelligence [1]. Patients with the
severe phenotype do not normally survive past the second or
third decade of life [97].
5.1. Morquio’s Syndrome Type A. Morquio’s syndrome A is
caused by mutations in the gene encoding galactosamine-6-
sulphate sulfatase (GALNS), which plays a crucial role on
the degradation of both keratan sulphate and chondroitin
sulphate.
The gene coding for human galactosamine-6-sulphate
sulfatase (GALNS), was mapped to chromosome 16q24.3
trough fluorescence in situ hybridization assays [98]. Its
structure was described at the same time by independent
groups as comprising 14 exons and spanning approximately
40–50 kb [99, 100]. Curiously, the GALNS gene contains an
Alu repeat in intron 5 and a VNTR-like sequence in intron 6
[100].
No natural occurring model is known for either type A
or type B Morquio’s syndrome. Nevertheless, a laboratorial
murine model for type A syndrome was created from
an induced disruption in exon 2 of the GALNS gene.
Mutants presented no detectable enzyme activity and showed
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increased GAG levels in urine. GAGs accumulation was also
detected in several tissues including liver, kidney, spleen,
heart, brain, and bone marrow [14]. These mice were
later tested for enzyme replacement therapy and, after a
12-week long treatment with native GALNS or SUMF1-
modified GALNS, showed manifest clinical improvement,
demonstrated by a marked reduction of storage material in
visceral organs, bone marrow, heart valves, ligaments, and
connective tissue. The clearance of stored material in brain
was dose dependent, and the keratan sulphate blood levels
were reduced to normal [101].
Presently, there is no eﬀective therapy for MPS IVA
and care has been palliative, as in the majority of LSDs.
Enzyme replacement therapy (ERT) and hematopoietic stem
cells therapy (HSCT) have been considered as potential
therapeutic approaches for MPS IVA (reviewed in [102]),
ERT being, though, the most attractive candidate, since
aﬀected patients lack CNS involvement.
Recently, Rodrı´guez et al. [103] have produced a recom-
binant GALNS enzyme in Escherichia coli BL21. To produce
suﬃcient amounts of purified GALNS enzyme, high level
expression of GALNS in Chinese hamster ovary (CHO) cells
has been established as a source of selectively secreted human
recombinant enzyme. This recombinant enzyme has already
been tested in themurine knock-out model, with consequent
clearance of tissue and blood keratan sulphate [101]. These
results provided important preclinical data for the design of
GALNS ERT trials, which are now in course.
5.2. Morquio’s Syndrome Type B. Although presenting over-
lapping clinical features, Morquio’s syndrome B is genetically
distinct from Morquio’s syndrome A, being caused by
impairments in another enzyme involved in the stepwise
degradation of keratan sulphate: β-galactosidase, which is
coded by the GLB1 gene. Beta galactosidase hydrolases ter-
minal β-linked galactose residues found in GM1 ganglioside,
glycoproteins, and oligosaccharides, as well as in keratan
sulphate (reviewed in [1]).
The GLB1 gene spans 62.5 kb and contains 16 exons
[104, 105] and maps to chromosome 3p21.33 [106]. The
deduced 677-residue protein has a calculated molecular mass
of 75 kD and contains a putative 23-residue signal sequence
and 7 potential asparagine-linked glycosylation sites. It may
be interesting to refer that the GLB1 gene gives rise to 2
alternatively spliced mRNAs: a major 2.5-kb transcript that
encodes the classic lysosomal form of the enzyme of 677
amino acids, and a minor 2.0-kb transcript that encodes a β-
galactosidase-related protein (elastin-binding protein, EBP)
of 546 amino acids with no enzymatic activity and a diﬀerent
subcellular localization. Exons 3, 4, and 6 are absent in the
2.0-kb mRNA as a consequence of alternative splicing of the
pre-mRNA [107–109].
Presently, there are no known animal models for MPS
IVB, either natural or engineered.
6. Mucopolysaccharidosis V
The designation MPS V is no longer used. In fact, the
phenotype which was first classified as MPS V, was later
found to be the milder form of MPS I (Scheie’s syndrome),
caused by deficiencies in α-L-iduronidase, with the typical
stiﬀ joints, clouding of the cornea most dense peripherally,
survival to a late age with little if any impairment of intellect
and aortic regurgitation [44].
7. Mucopolysaccharidosis VI
(Maroteaux-Lamy Syndrome)
Mucopolysaccharidosis type VI is an autosomal recessive
lysosomal storage disorder resulting from a deficiency of
arylsulfatase B (N-acetylgalactosamine-4-sulfatase). Clini-
cal features and severity are variable but usually include
short stature, hepatosplenomegaly, dysostosis multiplex, stiﬀ
joints, corneal clouding, cardiac abnormalities, and facial
dysmorphism. Intelligence is usually normal [110].
Arylsulfatase B is a lysosomal enzyme that removes the
C4 sulphate ester group from the N-acetylgalactosamine
sugar residue at the nonreducing terminus of dermatan
sulphate and chondroitin sulphate, during lysosomal degra-
dation [111]. The gene that codes for this enzyme was first
mapped to chromosome 5q11-q13 [112] and is now known
to contain 8 exons and span about 206 kb [111].
In 2002, a 3-year-old Siamese/short-haired European cat
was referred for clinical disease characterized by dwarfism,
facial dysmorphia, paralysis, small and curled ears, corneal
clouding, and large areas of alopecia. X-ray examination
showed multiple bone dysplasias. These features lead to
suspect from a mucopolysaccharide storage disorder. Subse-
quent analysis proved it to be a natural occurring form of the
Maroteaux-Lamy syndrome [15].
This MPS VI model has been extensively used over
the last years to test ERT for this specific pathology.
In 2003, Auclair and colleagues [113] have evaluated the
cats’ response to infusions of recombinant human N-
acetylgalactosamine-4-sulfatase (rhASB) and observed an
overall improvement in the disease condition at physical,
neurological, and skeletal levels. Later, the same team has
demonstrated that a high rate of immunotolerance towards
rhASB can be achieved in MPS VI cats with a short-course
tolerisation regimen [114], which may help the implementa-
tion of such procedures. Another interesting approach was
designed, specifically to ameliorate joint disease in MPS
IVA, through long-term articular administration of rhASB,
leading to a notorious improvement in feline joint disease
[115]. These successful results lead to the development
of clinical trials in MPS VI patients, and three clinical
studies including 56 patients have evaluated the eﬃcacy and
safety. As a consequence, enzyme replacement therapy (ERT)
became available. The specific ERT for MPS VI, galsulfase
(Naglazyme, Biomarin Pharmaceutical) was approved in
2005 by FDA and in 2006 by EMA. Long-term follow-up data
with patients treated up to 5 years showed that ERT is well
tolerated and associated with sustained improvements in the
patients’ clinical condition [2, 116].
Even though presently there is ERT available for these
patients, other therapeutic approaches are being tested in
animal models for MPS VI. In 2009, the first attempt of
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successful gene therapy was performed through lentiviral-
mediated gene transfer to joint tissues of the rat, with
consequent correction of MPS VI cells [117]. This year,
another study, involving intravascular administration of
adeno-associated viral vectors inMPS VI cats, was published.
After gene transfer the authors observed clearance of GAG
storage, improvement of long bone length, reduction of heart
valve thickness, and improvement in spontaneous mobility
[118]. Either way, promising therapeutic strategies for MPS
VI patients may be arising.
8. Mucopolysaccharidosis VII
(Sly’s Syndrome)
MPS VII, also known as Sly’s syndrome, is characterized
by the impossibility to degrade glucuronic acid-containing
GAGs, due to impaired function of β-glucuronidase, which
removes the glucuronic acid residues present in dermatan
sulphate as well as in heparan and chonroitin sulphates
(reviewed in [1]). Clinical features are highly variable, with
phenotypes ranging from severe fetal hydrops to mild forms
allowing survival into adulthood. Typical features include
hepatomegaly, skeletal abnormalities, coarse facial features,
and variable degrees of mental impairment [119].
MPS VII was first reported by Sly and collabora-
tors in 1973, in a boy with skeletal changes consistent
with MPS, hepatosplenomegaly, and granular inclusions in
granulocytes. Additional features included hernias, unusual
facies, protruding sternum, thoracolumbar gibbus, vertebral
deformities, and mental deficiency. When β-glucuronidase
activity was measured in fibroblasts, obtained values were
less than 2% of control values. Both parents and several sibs
of the mother showed an intermediate level of the enzyme
[120].
In 1990, Miller et al. [121] reported that the gene
encoding β-glucuronidase (GUSB) is 21 kb long, contains 12
exons, and gives rise to two diﬀerent types of cDNAs, through
an alternate splicing mechanism. Speleman et al. [122] used
fluorescence in situ hybridization to map the GUSB gene to
7q11.21-q11.22. This map position was confirmed by dual-
color hybridization of β-glucuronidase and another gene
which had been mapped proximal to it: elastin (7q11.23).
Several pseudogenes, located on chromosomes 5, 6, 7, 20,
22, and Y, were also detected by Shipley et al. [123], when
amplifying exons 2–4, 3, 6-7, and 11.
In 2009, Tomatsu et al. [124] provided a review of
mutations in the GUSB gene that cause MPS type VII. Forty-
nine diﬀerent pathogenic mutations have been reported
in the literature, with approximately 90% of them being
missense mutations. Approximately 40% of the known
GUSB mutations occur at CpG sites within the gene. The
most common mutation is L176F, which has been found
in several populations: American (Caucasian), Brazilian,
British, Chilean, French, Mexican, Polish, Spanish, and Turk-
ish ([125–127], reviewed in [124]). Genotype/phenotype
analysis indicated that the most severe phenotype was
associated with truncating mutations and with mutations
aﬀecting either the hydrophobic core or the modification of
packing.
In 1984, mucopolysaccharidosis type VII (Sly syndrome)
was described in a mixed-breed dog [16]. Since then,
several other aﬀected dogs have been studied, in the animal
colony established at the University of Pennsylvania, the
School of Veterinary Medicine [128] and, later, in a 12-
week-old male German Shepherd dog studied in the same
school [129]. All dogs shared the same missense mutation
and developed similar phenotypes with skeletal deformities,
corneal cloudiness, cytoplasmic granules in the neutrophils
and lymphocytes of blood and CSF, and glycosaminoglycans
in urine [129]. Another animal model was described as
naturally occurring: the gusmps/mps mouse, which has a 1 bp
deletion in exon 10 resulting in a progressive degenerative
disease that reduces lifespan and causes facial dysmorphism,
growth retardation, deafness, and behavioral defects [17].
Nevertheless, opportunities for experimental therapies were
greatly expanded by the work of Tomatsu et al., in 2006
[18], who developed a new MPS VII mouse model, which
is tolerant to both human and murine GUS, without the
characteristic immune responses that complicated evalua-
tion of the long-term benefits of enzyme replacement or gene
therapy when the naturally occurring mice were used. Ever
since, several therapeutic approaches have been attempted in
MPS VII mice, and the results have been encouraging. That
is the case of the works by Bosch and collaborators, who have
been working on gene therapy for this pathology, in order to
correct brain lesions. They have used both adeno-associated
virus (AAV) [130] and lentivirus-mediated gene transfer
[131] and observed that there was a significant correction of
pathology in the brain of aﬀected mice.
Other therapeutic approaches had already been attempt-
ed, but their results were not as promising. In fact, in 1998,
allogenic bone marrow transplantation was reported in a
12-year-old Japanese girl with consequent improvement of
motor function and daily life activities, decrease of upper
respiratory and ear infections, but no improvement at all in
cognitive function [132].
9. Mucopolysaccharidosis VIII
The clinical entity once known as MPS VIII was described
in a single patient, in the late 1970s. The patient, a 5-year-
old child, presented short stature, coarse hair, hepatomegaly,
mild dysostosis multiplex, mental retardation, and no signs
of corneal clouding. Biochemical analysis of the urine
revealed increased excretion of keratan and heparan sulphate
[133, 134]. The biochemical findings described by this group
lead to suspect the existence of two hexosamine sulfatases
and propose the existence of this novel MPS, caused by
glucosamine-6-sulfatase [133].
Nevertheless, subsequent analysis on Diferrante’s labora-
tory brought this idea down, and the designation MPS VIII
was abandoned [135].
10. Mucopolysaccharidosis IX
Mucopolysaccharidosis IX, also known as hyaluronidase
deficiency, is caused by mutations in the HYAL1 gene.
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This disease was first discovered by Natowicz et al.
[136] in a 14-year-old girl with short stature and multi-
ple periarticular soft-tissue masses. Radiographic analysis
showed nodular synovia, acetabular erosions, and a popliteal
cyst. Lysosomal storage of hyaluronan (HA) was evident
within the macrophages and fibroblasts of biopsied soft-
tissue masses, and serum concentrations were elevated
38–90-fold. She was proven to have a storage disease of
hyaluronan (hyaluronic acid) due to a genetic deficiency of
hyaluronidase. The descriptions of hyaluronidase deficiency
in this family are consistent with autosomal recessive inheri-
tance.
In order to determine the molecular basis of MPS IX,
Triggs-Raine et al. [137] analyzed 2 diﬀerent candidate
genes tandemly distributed on chromosome 3p21.3, both
encoding proteins with homology to a sperm enzyme with
hyaluronidase activity. These genes, HYAL1 and HYAL2,
encode 2 distinct lysosomal hyaluronidases with diﬀerent
substrate specificities. When characterizing the patient with
hyaluronidase deficiency originally reported in [136], they
verified that he was a compound heterozygote for 2 muta-
tions in the HYAL1 gene: a missense mutation (c.1412G>A),
which introduced a nonconservative amino acid substitution
in a putative active site residue (p.Glu268Lys) and a complex
intragenic rearrangement, 1361del37ins14, which resulted in
a premature termination codon. Through this work, they
have also showed that these 2 hyaluronidase genes, together
with a third adjacent HYAL3 gene, had markedly diﬀerent
tissue expression patterns, consistent with diﬀering roles in
the metabolism of hyaluronan. These findings allowed this
team not only to explain the unexpectedly mild phenotype
of MPS IX but also to predict the existence of other
hyaluronidase-deficiency disorders.
Presently, three other hyaluronidase-related genes
(HYAL4, HYALP1, SPAM1) have been identified at 7q31.3
[138]. These genes are predicted to encode hyaluronidases,
endoglycosidases that initiate the degradation of HA, a large
negatively charged GAG found in the extracellular matrix
(ECM) of all vertebrate cells [19].
Since there is only one patient reported to date, the
development and characterization of a model of Hyal1
deficiency was the first logical step in understanding themain
phenotypic symptoms associated with MPS IX. During this
decade, a mouse model for MPS IX has become available and
was fully characterized [19]. Overall, it was observed that
the murine MPS IX model displays the key features of the
human disease. Nevertheless, during the same year, another
mutant mouse suﬀering from a hyaluronidase deficiency
was described, this one deficient in HYAL2 [139]. Skeletal
and hematological anomalies were described in this model,
raising the possibility that a similar defect, defining a new
MPS disorder, exists in humans [139].
11. Conclusion
The elucidation of enzyme deficiencies underlying mucopol-
ysaccharidoses was crucial to unveil the normal pathways
of glycosaminoglycan catabolism. In fact, only through the
consequences of their absence became the role of several
enzymes evident. The majority of these enzyme deficiencies
were discovered during the 1970s. Over the last decades
the enzyme deficiencies underlying each disease, and the
molecular defects causing them have been identified and
extensively analyzed and characterized. As a result, six
diﬀerent MPS are known, caused by deficiencies in one
of the ten diﬀerent enzymes necessary to intralysosomal
degradation of GAGs through one of the four diﬀerent
degradation pathways.
Each disease has its own hallmark features. Neverthe-
less, a common pattern arouses: MPS are usually chronic,
with a progressive course and diﬀerent severity degrees.
Organomegaly, dysostosis multiplex, and CNS involvement
are common but not necessary features.
Over the years, several MPS have been recognized in ani-
mals as naturally occurring diseases, and others were created
by knock-out technology. Most animal colonies have been
established from single related heterozygous animals, in such
a way that the aﬀected oﬀspring is homozygous for the same
mutant allele. All these models present disease pathology
similar to that seen in humans, making the animals extremely
valuable for both investigation of disease pathogenesis and
testing of therapies. Large animal homologues are similar to
humans in natural genetic diversity, approaches to therapy
and care, and possibility of evaluating long-term eﬀects of
treatment. Presently, therapeutic strategies for MPS include
enzyme replacement therapy, heterologous bone marrow
transplantation, and somatic cell gene transfer, all of which
have been tested in animals with some success. During the
80s, transplantation of hematopoietic stem cells was tested
for several MPSs. Theoretically, haematopoietic stem cells
taken from a normal compatible donor and transplanted
into an enzyme-deficient recipient can provide a safe,
permanent, and self-replicating source of bone marrow-
derived cells. By secreting active lysosomal enzymes, these
cells cross-connect nonbone marrow-derived cells. Several
animal models for GAGs storage diseases have already
been subjected to/undergone BMT. From those experiments,
along with human clinical trials already tried, it was possible
to verify that there are important variations in therapeutic
response among diﬀerent pathologies with some diseases
with CNS pathology which can be successfully treated by
BMT (the severe form of MPS I, being the example for
the GAG storage disorders; [140]) whereas others cannot
(MPS II and III in which BMT was tested with few success;
[3, 141]). These variations are usually attributed to the
diﬀerent capacities of secretion, stability, and uptake of
each specific enzyme. Nevertheless, important conclusions
could be drawn from the collective experience of postnatal
transplantation including the idea that the earlier the
transplants are performed, the better the clinical response. In
the 90s; however, a novel approach started to be tested: ERT.
Nowadays, it has been the most tested approach in animal
models of GAG storage disorders. Until now, the obtained
results have been highlighting the potential of administered
recombinant enzyme to reduce GAG accumulation. ERTs are
presently available for MPS I (since 2003), II (since 2005),
and VI (since 2006). Clinical trials are also in course for MPS
IVA treatment through ERT. Nevertheless, this approach is
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ineﬀective for the brain since recombinant enzymes are not
able to cross the blood-brain barrier (BBB). This is one of the
reasons why other therapies are being tested for MPS with
CNS involvement. ERT with direct administration of the
recombinant enzyme into the brain (intrathecal injections)
is also being considered in order to overcome that diﬃculty.
Presently, such approaches are being considered forMPS IIIA
and to overcome the cognitive deficit of MPS II and MPS I
(reviewed in [142]).
Somatic cell gene transfer is another possible approach,
but a long way needs yet to be travelled towards such a
therapy is applicable to patients.
Finally, substrate deprivation therapy (or substrate
reduction therapy) is also being considered for some MPSs.
This approach is being tested with both genistein and
rhodamine B (reviewed in [70]). Genistein, a chemical from
the group of isoflavones, has been shown to inhibit the
synthesis of GAGs in fibroblasts of patients with various
forms of MPSs, namely, types I, II, IIIA, and IIIB [4, 143].
Similar results were obtained with rhodamine B, an inhibitor
with an unknownmechanism of action. Remarkably, in MPS
IIIA mice treated with rhodamine B, GAG storage decreased
not only in somatic tissues, but also in brain, with improved
behaviours of the animals [144, 145]. These encouraging
results lead to the development of open-label pilot clinical
studies with children suﬀering from Sanfilippo’s syndrome
types A and B in which a genistein-rich isoflavone extract
(SE-2000, Biofarm, Poland) orally administered for 12
months. After one year of treatment, statistically significant
improvement in all tested parameters was demonstrated
(reviewed in [70]).
In order to better quantify and assess the eﬃcacy of
these therapeutic approaches, investigators have been trying
to indentify suitable biomarkers for MPS, which allow the
evaluation of short- and long-term treatment eﬀects. This is
also assuming particular importance since early detection of
MPS is an important factor in treatment success. Recently
discovered biomarkers include heparin cofactor II-thrombin
complex and dermatan sulphate:chondroitin sulphate ratio
[146]. Other biomarkers and/or therapeutic targets for MPS
joint and bone disease recently identified through animal
studies include several proinflammatory cytokines, nitric
oxide, and matrix metalloproteinases (MMPs; [147]).
Another hot topic which is recently being discussed refers
to the possibility of including someMPSs (particularly type I,
IIIA, IIIB, and VI) in neonatal screening programs [148]. The
ongoing development of enzyme replacement therapy and
other treatments for several LSDs, includingMPSs combined
with the growing evidence that early commencement of
therapy improves outcomes, has increased the pressure for
the introduction of newborn screening programs, and a
number of pilot studies are ongoing [148–152]. This is only
possible thanks to the significant advances that were made in
last decade since dried blood spot technology was introduced
for enzymatic assays and lysosomal protein profile was
developed.
Overall, there are encouraging results, with some ther-
apeutic approaches already approved and others under
development. Either way, it is important to stress that the
management of MPS requires lifelong attention to the mul-
tisystemic involvement by a team of specialists experienced
in dealing with these diseases, since none of the therapeutic
options currently available result in complete resolution of
morbidity.
References
[1] E. F. Neufeld and J. Muenzer, “The mucopolysaccharidoses,”
in The Metabolic & Molecular Bases of Inherited Disease, C.
R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds., vol. 3,
McGraw–Hill, New York, NY, USA, 8th edition, 2001.
[2] R. Giugliani, C. G. Carvalho, S. Herber, and L. L. de
Camargo Pinto, “Recent advances in treatment approaches of
mucopolysaccharidosis VI,” Current Pharmaceutical Biotech-
nology, vol. 12, no. 6, pp. 956–962, 2011.
[3] M. Haskins, M. Casal, N. M. Ellinwood, J. Melniczek, H.
Mazrier, and U. Giger, “Animal models for mucopolysaccha-
ridoses and their clinical relevance,” Acta Paediatrica, vol. 91,
no. 439, supplement, pp. 88–97, 2002.
[4] E. Piotrowska, J. Jako´bkiewicz-Banecka, S. Baran´ska et
al., “Genistein-mediated inhibition of glycosaminoglycan
synthesis as a basis for gene expression-targeted isoflavone
therapy for mucopolysaccharidoses,” European Journal of
Human Genetics, vol. 14, no. 7, pp. 846–852, 2006.
[5] M. E. Haskins, P. F. Jezyk, R. J. Desnick, S. K. McDonaugh,
and D. F. Patterson, “Alpha L iduronidase deficiency in a cat:
a model of mucopolysaccharidosis I,” Pediatric Research, vol.
13, no. 11, pp. 1294–1297, 1979.
[6] R. M. Shull, R. J. Munger, and E. Spellacy, “Canine α-L-
iduronidase deficiency. Amodel of mucopolysaccharidosis I,”
American Journal of Pathology, vol. 109, no. 2, pp. 244–248,
1982.
[7] L. A. Clarke, C. S. Russell, S. Pownall et al., “Murine
mucopolysaccharidosis type I: targeted disruption of the
murine α-L-iduronidase gene,” Human Molecular Genetics,
vol. 6, no. 4, pp. 503–511, 1997.
[8] M. J. Wilkerson, D. C. Lewis, S. L. Marks, and D. J. Prieur,
“Clinical and morphologic features of mucopolysaccharido-
sis type II in a dog: naturally occurring model of Hunter
syndrome,” Veterinary Pathology, vol. 35, no. 3, pp. 230–233,
1998.
[9] A. R. Garcia, J. Pan, J. C. Lamsa, and J. Muenzer, “The char-
acterization of a murine model of mucopolysaccharidosis II
(Hunter syndrome),” Journal of Inherited Metabolic Disease,
vol. 30, no. 6, pp. 924–934, 2007.
[10] A. Fischer, K. P. Carmichael, J. F. Munnell et al., “Sulfamidase
deficiency in a family of dachshunds: a canine model
of mucopolysaccharidosis IIIA (Sanfilippo A),” Pediatric
Research, vol. 44, no. 1, pp. 74–82, 1998.
[11] R. Bhattacharyya, B. Gliddon, T. Beccari, J. J. Hopwood,
and P. Stanley, “A novel missense mutation in lysosomal
sulfamidase is the basis of MPS III A in a spontaneous mouse
mutant,” Glycobiology, vol. 11, no. 1, pp. 99–103, 2001.
[12] N. M. Ellinwood, P. Wang, T. Skeen et al., “A model
of mucopolysaccharidosis IIIB (Sanfilippo syndrome type
IIIB): N-acetyl-α-D-glucosaminidase deficiency in Schip-
perke dogs,” Journal of Inherited Metabolic Disease, vol. 26,
no. 5, pp. 489–504, 2003.
[13] J. N. Thompson, M. Z. Jones, G. Dawson, and P. S. Huﬀman,
“N-acetylglucosamine 6-sulphatase deficiency in a Nubian
12 Biochemistry Research International
goat: a model of Sanfilippo syndrome type D (mucopoly-
saccharidosis IIID),” Journal of Inherited Metabolic Disease,
vol. 15, no. 5, pp. 760–768, 1992.
[14] S. Tomatsu, K. O. Orii, C. Vogler et al., “Mouse model on
N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-
/-) produced by targeted disruption of the gene defective in
Morquio A disease,” Human Molecular Genetics, vol. 12, no.
24, pp. 3349–3358, 2003.
[15] B. MacRı`, F. Marino, G. Mazzullo et al., “Mucopolysacchari-
dosis VI in a Siamese/short-haired European cat,” Journal of
Veterinary Medicine A, vol. 49, no. 8, pp. 438–442, 2002.
[16] M. E. Haskins, R. J. Desnick, and N. DiFerrante, “β-
glucuronidase deficiency in a dog: a model of human
mucopolysaccharidosis VII,” Pediatric Research, vol. 18, no.
10, pp. 980–984, 1984.
[17] E. H. Birkenmeier, M. T. Davisson, W. G. Beamer et al.,
“Murine mucopolysaccharidosis type VII. Characterization
of a mouse with β-glucuronidase deficiency,” Journal of
Clinical Investigation, vol. 83, no. 4, pp. 1258–1266, 1989.
[18] S. Tomatsu, K. Sukegawa, G. G. Trandafirescu et al., “Diﬀer-
ences in methylation patterns in the methylation boundary
region of IDS gene in hunter syndrome patients: implications
for CpG hot spot mutations,” European Journal of Human
Genetics, vol. 14, no. 7, pp. 838–845, 2006.
[19] D. C. Martin, V. Atmuri, R. J. Hemming et al., “A
mouse model of human mucopolysaccharidosis IX exhibits
osteoarthritis,”HumanMolecular Genetics, vol. 17, no. 13, pp.
1904–1915, 2008.
[20] V. A. McKusick, Heritable Disorders of Connective Tissue,
Mosby, St. Louis, Mo, USA, 4th edition, 1972.
[21] H. S. Scott, X. H. Guo, J. J. Hopwood, and C. P. Morris,
“Structure and sequence of the human α-L-iduronidase
gene,” Genomics, vol. 13, no. 4, pp. 1311–1313, 1992.
[22] H. S. Scott, L. J. Ashton, H. J. Eyre et al., “Chromosomal
localization of the human α-L-iduronidase gene (IDUA) to
4p16.3,” American Journal of Human Genetics, vol. 47, no. 5,
pp. 802–807, 1990.
[23] E. Spellacy, R. M. Shull, G. Constantopoulos, and E. F.
Neufeld, “A canine model of human α-L-iduronidase defi-
ciency,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 80, no. 19, pp. 6091–6095, 1983.
[24] L. J. Stoltzfus, B. Sosa-Pineda, S. M. Moskowitz et al.,
“Cloning and characterization of cDNA encoding canine α-
L-iduronidase. mRNA deficiency in mucopolysaccharidosis
I dog,” Journal of Biological Chemistry, vol. 267, no. 10, pp.
6570–6575, 1992.
[25] K. P. Menon, P. T. Tieu, and E. F. Neufeld, “Architecture
of the canine IDUA gene and mutation underlying canine
mucopolysaccharidosis I,” Genomics, vol. 14, no. 3, pp. 763–
768, 1992.
[26] R. M. Shull, E. D. Kakkis, M. F. McEntee, S. A. Kania, A. J.
Jonas, and E. F. Neufeld, “Enzyme replacement in a canine
model of Hurler syndrome,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 91,
no. 26, pp. 12937–12941, 1994.
[27] C. L. S. Grosson, M. E. MacDonald, M. P. Duyao, C. M.
Ambrose, S. Roﬄer Tarlov, and J. F. Gusella, “Synteny con-
servation of the Huntington’s disease gene and surrounding
loci on mouse chromosome 5,” Mammalian Genome, vol. 5,
no. 7, pp. 424–428, 1994.
[28] C. Russell, G. Hendson, G. Jevon et al., “Murine MPS I:
insights into the pathogenesis of Hurler syndrome,” Clinical
Genetics, vol. 53, no. 5, pp. 349–361, 1998.
[29] C. Peters, E. G. Shapiro, and W. Krivit, “Neuropsychological
development in children with Hurler syndrome following
hematopoietic stem cell transplantation,” Pediatric Trans-
plantation, vol. 2, no. 4, pp. 250–253, 1998.
[30] C. Peters, E. G. Shapiro, and W. Krivit, “Hurler syndrome:
past, present, and future,” Journal of Pediatrics, vol. 133, no.
1, pp. 7–9, 1998.
[31] S. L. Staba, M. L. Escolar, M. Poe et al., “Cord-blood
transplants from unrelated donors in patients with Hurler’s
syndrome,” New England Journal of Medicine, vol. 350, no.
19, pp. 1960–1969, 2004.
[32] J. J. Boelens, R. F. Wynn, A. O’Meara et al., “Outcomes
of hematopoietic stem cell transplantation for Hurler’s
syndrome in Europe: a risk factor analysis for graft failure,”
Bone Marrow Transplantation, vol. 40, no. 3, pp. 225–233,
2007.
[33] L. A. Clarke, J. E. Wraith, M. Beck et al., “Long-term eﬃcacy
and safety of laronidase in the treatment of mucopolysaccha-
ridosis I,” Pediatrics, vol. 123, no. 1, pp. 229–240, 2009.
[34] J. E. Wraith, L. A. Clarke, M. Beck et al., “Enzyme replace-
ment therapy for mucopolysaccharidosis I: a randomized,
double-blinded, placebo-controlled, multinational study of
recombinant human α-L-iduronidase (laronidase),” Journal
of Pediatrics, vol. 144, no. 5, pp. 581–588, 2004.
[35] H. Harada, H. Uchiwa, M. Nakamura et al., “Laronidase
replacement therapy improves myocardial function
in mucopolysaccharidosis I,” Molecular Genetics and
Metabolism, vol. 103, no. 3, pp. 215–219, 2011.
[36] A. Tylki-Szymanska, J. Marucha, A. Jurecka, M. Syczewska,
and B. Czartoryska, “Eﬃcacy of recombinant human α-L-
iduronidase (laronidase) on restricted range of motion of
upper extremities in mucopolysaccharidosis type i patients,”
Journal of Inherited Metabolic Disease, vol. 33, no. 2, pp. 151–
157, 2010.
[37] A. Tylki-Szymanska, A. Rozdzynska, A. Jurecka, J. Marucha,
and B. Czartoryska, “Anthropometric data of 14 patients with
mucopolysaccharidosis I: retrospective analysis and eﬃcacy
of recombinant human α-l-iduronidase (laronidase),” Molec-
ular Genetics and Metabolism, vol. 99, no. 1, pp. 10–17, 2010.
[38] O. Gabrielli, L. A. Clarke, S. Bruni, and G. V. Coppa,
“Enzyme-replacement therapy in a 5-month-old boy with
attenuated presymptomatic MPS I: 5-year follow-up,” Pedi-
atrics, vol. 125, no. 1, pp. e183–e187, 2010.
[39] J. E. Wraith, J. G. Rogers, and D. M. Danks, “The
mucopolysaccharidoses,” Australian Paediatric Journal, vol.
23, no. 6, pp. 329–334, 1987.
[40] R. J. Gorlin, M. M. Cohen Jr., and R. C. M. Hennekam,
Syndromes of the Head and Neck, Oxford University Press,
New York, NY, USA, 4th edition, 2001.
[41] M. D. C. Donaldson, C. A. Pennock, P. J. Berry, A. W.
Duncan, J. E. Cawdery, and J. V. Leonard, “Hurler syndrome
with cardiomyopathy in infancy,” Journal of Pediatrics, vol.
114, no. 3, pp. 430–432, 1989.
[42] J. Shapiro, M. Strome, and A. C. Crocker, “Airway obstruc-
tion and sleep apnea in Hurler and Hunter syndromes,”
Annals of Otology, Rhinology and Laryngology, vol. 94, no. 5
I, pp. 458–461, 1985.
[43] M. Hanson, J. R. Lupski, J. Hicks, and D. Metry, “Association
of dermal melanocytosis with lysosomal storage disease:
clinical features and hypotheses regarding pathogenesis,”
Archives of Dermatology, vol. 139, no. 7, pp. 916–920, 2003.
[44] V. A. McKusick, D. Kaplan, D. Wise et al., “The genetic
mucopolysaccharidoses,” Medicine, vol. 44, no. 6, pp. 445–
483, 1965.
Biochemistry Research International 13
[45] C. B. Whitley, “The mucopolysaccharidoses,” in McKusick’s
Heritable Disorders of Connective Tissue, P. Beighton, Ed.,
Mosby, St. Louis, Mo, USA, 5th edition, 1993.
[46] W. H. Perks, R. A. Cooper, and S. Bradbury, “Sleep apnoea in
Scheie’s syndrome,” Thorax, vol. 35, no. 2, pp. 85–91, 1980.
[47] J. E. Wraith, M. Scarpa, M. Beck et al., “Mucopolysac-
charidosis type II (Hunter syndrome): a clinical review
and recommendations for treatment in the era of enzyme
replacement therapy,” European Journal of Pediatrics, vol. 167,
no. 3, pp. 267–277, 2008.
[48] P. J. Wilson, G. K. Suthers, D. F. Callen et al., “Frequent
deletions at Xq28 indicate genetic heterogeneity in Hunter
syndrome,” Human Genetics, vol. 86, no. 5, pp. 505–508,
1991.
[49] R. H. Flomen, E. P. Green, P. M. Green, D. R. Bentley, and
F. Giannelli, “Determination of the organisation of coding
sequences within the iduronate sulphate sulphatase (IDS)
gene,” Human Molecular Genetics, vol. 2, no. 1, pp. 5–10,
1993.
[50] P. J. Wilson, C. A. Meaney, J. J. Hopwood, and C. P. Morris,
“Sequence of the human iduronate 2-sulfatase (IDS) gene,”
Genomics, vol. 17, no. 3, pp. 773–775, 1993.
[51] M. L. Bondeson, H. Malmgren, N. Dahl, B. M. Carlberg,
and U. Pettersson, “Presence of an IDS-related locus (IDS2)
and Xq28 complicates the mutational analysis of Hunter
syndrome,” European Journal of Human Genetics, vol. 3, no.
4, pp. 219–227, 1995.
[52] C. Peters, M. Balthazor, E. G. Shapiro et al., “Outcome of
unrelated donor bone marrow transplantation in 40 children
with Hurler syndrome,” Blood, vol. 87, no. 11, pp. 4894–4902,
1996.
[53] G. V. Coppa, O. Gabrielli, L. Zampini et al., “Bone marrow
transplantation in Hunter syndrome (mucopolysaccharido-
sis type II): two year follow-up of the first Italian patient and
review of the literature,” Pediatria Medica e Chirurgica, vol.
17, no. 3, pp. 227–235, 1995.
[54] E. J. R. McKinnis, S. Sulzbacher, J. C. Rutledge, J. Sanders,
and C. R. Scott, “Bone marrow transplantation in Hunter
syndrome,” Journal of Pediatrics, vol. 129, no. 1, pp. 145–148,
1996.
[55] T. A. Burrow and N. D. Leslie, “Review of the use of
idursulfase in the treatment of mucopolysaccharidosis II,”
Biologics, vol. 2, pp. 311–320, 2008.
[56] J. Muenzer, J. C. Lamsa, A. Garcia, J. Dacosta, J. Garcia, and
D. A. Treco, “Enzyme replacement therapy in mucopolysac-
charidosis type II (Hunter syndrome): a preliminary report,”
Acta Paediatrica, vol. 91, no. 439, supplement, pp. 98–99,
2002.
[57] A. R. Garcia, J. M. DaCosta, J. Pan, J. Muenzer, and J.
C. Lamsa, “Preclinical dose ranging studies for enzyme
replacement therapy with idursulfase in a knock-out mouse
model of MPS II,” Molecular Genetics and Metabolism, vol.
91, no. 2, pp. 183–190, 2007.
[58] J. Muenzer, M. Gucsavas-Calikoglu, S. E. McCandless, T. J.
Schuetz, and A. Kimura, “A phase I/II clinical trial of enzyme
replacement therapy in mucopolysaccharidosis II (Hunter
syndrome),” Molecular Genetics and Metabolism, vol. 90, no.
3, pp. 329–337, 2007.
[59] J. Muenzer, J. E. Wraith, M. Beck et al., “A phase II/III clinical
study of enzyme replacement therapy with idursulfase in
mucopolysaccharidosis II (Hunter syndrome),” Genetics in
Medicine, vol. 8, no. 8, pp. 465–473, 2006.
[60] F. Papadia, M. S. Lozupone, A. Gaeta, D. Capodiferro, and
G. Lacalendola, “Long-term enzyme replacement therapy in
a severe case of mucopolysaccharidosis type II (Hunter syn-
drome),” European Review for Medical and Pharmacological
Sciences, vol. 15, no. 3, pp. 253–258, 2011.
[61] L. Filippon, C. A. Y. Wayhs, D. M. Atik et al., “DNA damage
in leukocytes from pretreatment mucopolysaccharidosis type
II patients; protective eﬀect of enzyme replacement therapy,”
Mutation Research, vol. 721, no. 2, pp. 206–210, 2011.
[62] L. Filippon, C. S. Vanzin, G. B. Biancini et al., “Oxidative
stress in patients with mucopolysaccharidosis type II before
and during enzyme replacement therapy,” Molecular Genetics
and Metabolism, vol. 103, no. 2, pp. 121–127, 2011.
[63] J. J. P. Van De Kamp, M. F. Niermeijer, K. Von Figura,
and M. A. H. Giesberts, “Genetic heterogeneity and clinical
variability in the Sanfilippo syndrome (types A, B, and C),”
Clinical Genetics, vol. 20, no. 2, pp. 152–160, 1981.
[64] H. S. Scott, L. Blanch, X. H. Guo et al., “Cloning of
the sulphamidase gene and identification of mutations in
Sanfilippo A syndrome,” Nature Genetics, vol. 11, no. 4, pp.
465–467, 1995.
[65] L. E. Karageorgos, X. H. Guo, L. Blanch et al., “Structure and
sequence of the human sulphamidase gene,” DNA Research,
vol. 3, no. 4, pp. 269–271, 1996.
[66] E. L. Aronovich, K. P. Carmichael, H. Morizono et al.,
“Canine heparan sulfate sulfamidase and the molecu-
lar pathology underlying Sanfilippo syndrome type A in
Dachshunds,” Genomics, vol. 68, no. 1, pp. 80–84, 2000.
[67] K. M. Hemsley and J. J. Hopwood, “Development of motor
deficits in a murine model of mucopolysaccharidosis type
IIIA (MPS-IIIA),” Behavioural Brain Research, vol. 158, no.
2, pp. 191–199, 2005.
[68] C. Settembre, A. Fraldi, L. Jahreiss et al., “A block of
autophagy in lysosomal storage disorders,” Human Molecular
Genetics, vol. 17, no. 1, pp. 119–129, 2008.
[69] A. L. K. Roberts, B. J. Thomas, A. S. Wilkinson, J. M. Fletcher,
and S. Byers, “Inhibition of glycosaminoglycan synthesis
using rhodamine B in a mouse model of mucopolysaccha-
ridosis type IIIA,” Pediatric Research, vol. 60, no. 3, pp. 309–
314, 2006.
[70] J. Jako´bkiewicz-Banecka, A. Wegrzyn, and G. Wegrzyn,
“Substrate deprivation therapy: a new hope for patients
suﬀering from neuronopathic forms of inherited lysosomal
storage diseases,” Journal of Applied Genetics, vol. 48, no. 4,
pp. 383–388, 2007.
[71] D. Dziedzic, G. Wgrzyn, and J. Jako´bkiewicz-Banecka, “Im-
pairment of glycosaminoglycan synthesis in mucopolysac-
charidosis type IIIA cells by using siRNA: a potential ther-
apeutic approach for Sanfilippo disease,” European Journal of
Human Genetics, vol. 18, no. 2, pp. 200–205, 2010.
[72] A. Fraldi, K. Hemsley, A. Crawley et al., “Functional
correction of CNS lesions in an MPS-IIIA mouse model
by intracerebral AAV-mediated delivery of sulfamidase and
SUMF1 genes,” Human Molecular Genetics, vol. 16, no. 22,
pp. 2693–2702, 2007.
[73] H. G. Zhao, H. H. Li, A. Schmidtchen, G. Bach, and
E. F. Neufeld, “The gene encoding alpha-N-acetylglucosam-
inidase and mutations underlying Sanfilippo B syndrome,”
American Journal of Human Genetics, vol. 57, p. A185, 1995.
[74] H. G. Zhao, H. H. Li, G. Bach, A. Schmidtchen, and E. F.
Neufeld, “The molecular basis of Sanfilippo syndrome type
B,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 93, no. 12, pp. 6101–6105, 1996.
14 Biochemistry Research International
[75] H. H. Li, W. H. Yu, N. Rozengurt et al., “Mouse model of
Sanfilippo syndrome type B produced by targeted disruption
of the gene encoding alpha-N-acetylglucosaminidase,” Proc
Natl Acad Sci USA, vol. 96, no. 5, pp. 14505–14510, 1999.
[76] W. H. Yu, K. W. Zhao, S. Ryazantsev, N. Rozengurt, and E.
F. Neufeld, “Short-term enzyme replacement in the murine
model of sanfilippo syndrome type B,” Molecular Genetics
and Metabolism, vol. 71, no. 4, pp. 573–580, 2000.
[77] K. W. Zhao and E. F. Neufeld, “Purification and character-
ization of recombinant human α-N-acetylglucosaminidase
secreted by Chinese hamster ovary cells,” Protein Expression
and Purification, vol. 19, no. 1, pp. 202–211, 2000.
[78] B. Weber, J. J. Hopwood, and G. Yogalingam, “Expression
and characterization of human recombinant and α-N-
actylglucosaminidase,” Protein Expression and Purification,
vol. 21, no. 2, pp. 251–259, 2001.
[79] M. Beck, “New therapeutic options for lysosomal storage
disorders: enzyme replacement, small molecules and gene
therapy,” Human Genetics, vol. 121, no. 1, pp. 1–22, 2007.
[80] H. Fu, R. J. Samulski, T. J. McCown, Y. J. Picornell,
D. Fletcher, and J. Muenzer, “Neurological correction of
lysosomal storage in a mucopolysaccharidosis IIIB mouse
model by adeno-associated virus-mediated gene delivery,”
Molecular Therapy, vol. 5, no. 1, pp. 42–49, 2002.
[81] A. Cressant, N. Desmaris, L. Verot et al., “Improved behavior
and neuropathology in the mouse model of sanfilippo
type IIIB disease after adeno-associated virus-mediated gene
transfer in the striatum,” Journal of Neuroscience, vol. 24, no.
45, pp. 10229–10239, 2004.
[82] C. D. Heldermon, K. K. Ohlemiller, E. D. Herzog et al.,
“Therapeutic eﬃcacy of bone marrow transplant, intracra-
nial AAV-mediated gene therapy, or both in themousemodel
of MPS IIIB,” Molecular Therapy, vol. 18, no. 5, pp. 873–880,
2010.
[83] P. Di Natale, C. Di Domenico, N. Gargiulo et al., “Treatment
of the mouse model of mucopolysaccharidosis type IIIB with
lentiviral-NAGLU vector,” Biochemical Journal, vol. 388, no.
2, pp. 639–646, 2005.
[84] G. R. D. Villani, A. Follenzi, B. Vanacore, C. Di Domenico, L.
Naldini, and P. Di Natale, “Correction of mucopolysacchari-
dosis type IIIB fibroblasts by lentiviral vector-mediated gene
transfer,” Biochemical Journal, vol. 364, no. 3, pp. 747–753,
2002.
[85] C. Di Domenico, G. R. D. Villani, D. Di Napoli et al.,
“Intracranial gene delivery of LV-NAGLU vector corrects
neuropathology in murine MPS IIIB,” American Journal of
Medical Genetics A, vol. 149, no. 6, pp. 1209–1218, 2009.
[86] X. Fan, H. Zhang, S. Zhang et al., “Identification of the gene
encoding the enzyme deficient in mucopolysaccharidosis
IIIC (Sanfilippo disease type C),”American Journal of Human
Genetics, vol. 79, no. 4, pp. 738–744, 2006.
[87] M. Hrˇebı´cˇek, L. Mra´zova´, V. Seyrantepe et al., “Mutations in
TMEM76∗ cause mucopolysaccharidosis IIIC (Sanfilippo C
syndrome),”American Journal of HumanGenetics, vol. 79, no.
5, pp. 807–819, 2006.
[88] M. Feldhammer, S. Durand, and A. V. Pshezhetsky, “Pro-
tein misfolding as an underlying molecular defect in
mucopolysaccharidosis III type C,” PloS one, vol. 4, no. 10,
article e7434, 2009.
[89] S. Durand, M. Feldhammer, E. Bonneil, P. Thibault, and A.
V. Pshezhetsky, “Analysis of the biogenesis of heparan sulfate
acetyl-CoA: α- glucosaminide N-acetyltransferase provides
insights into the mechanism underlying its complete defi-
ciency in mucopolysaccharidosis IIIC,” Journal of Biological
Chemistry, vol. 285, no. 41, pp. 31233–31242, 2010.
[90] A. O. Fedele and J. J. Hopwood, “Functional analysis of the
HGSNAT gene in patients with mucopolysaccharidosis IIIC
(Sanfilippo C syndrome),” Human Mutation, vol. 31, no. 7,
pp. E1574–E1586, 2010.
[91] C. Freeman, P. R. Clements, and J. J. Hopwood, “Human
liver N-acetylglucosamine-6-sulphate sulphatase. Purifica-
tion and characterization,” Biochemical Journal, vol. 246, no.
2, pp. 347–354, 1987.
[92] C. Freeman and J. J. Hopwood, “Human liver N-
acetylglucosamine-6-phosphate sulphatase. Catalytic prop-
erties,” Biochemical Journal, vol. 246, no. 2, pp. 355–365,
1987.
[93] D. A. Robertson, D. F. Callen, E. G. Baker, C. P. Morris,
and J. J. Hopwood, “Chromosomal localization of the gene
for human glucosamine-6-sulphatase to 12q14,” Human
Genetics, vol. 79, no. 2, pp. 175–178, 1988.
[94] A. Mok, H. Cao, and R. A. Hegele, “Genomic basis of
mucopolysaccharidosis type IIID (MIM 252940) revealed
by sequencing of GNS encoding N-acetylglucosamine-6-
sulfatase,” Genomics, vol. 81, no. 1, pp. 1–5, 2003.
[95] C. E. Beesley, D. Burke, M. Jackson, A. Vellodi, B. G. Winch-
ester, and E. P. Young, “Sanfilippo syndrome type D: identi-
fication of the first mutation in the N-acetylglucosamine-6-
sulphatase gene,” Journal of Medical Genetics, vol. 40, no. 3,
pp. 192–194, 2003.
[96] E. Downs-Kelly, M. Z. Jones, J. Alroy et al., “Caprine
mucopolysaccharidosis IIID: a preliminary trial of enzyme
replacement therapy,” Journal of Molecular Neuroscience, vol.
15, no. 3, pp. 251–262, 2000.
[97] A. M. Montan˜o, S. Tomatsu, A. Brusius, M. Smith, and T.
Orii, “Growth charts for patients aﬀected with Morquio A
disease,” American Journal of Medical Genetics A, vol. 146, no.
10, pp. 1286–1295, 2008.
[98] S. Tomatsu, S. Fukuda, M. Masue, K. Sukegawa, M.
Masuno, and T. Orii, “Mucopolysaccharidosis type IVA:
characterization and chromosomal localization of N-
acetylgalactosamine-6-sulfate sulfatase gene and genetic het-
erogeneity,” American Journal of Human Genetics, vol. 51, p.
A178, 1992.
[99] Y. Nakashima, S. Tomatsu, T. Hori et al., “Mucopolysac-
charidosis IV A: molecular cloning of the human N-
acetylgalactosamine-6-sulfatase gene (GALNS) and analysis
of the 5’-flanking region,” Genomics, vol. 20, no. 1, pp. 99–
104, 1994.
[100] C. P. Morris, X. H. Guo, S. Apostolou, J. J. Hopwood, and
H. S. Scott, “Morquio A syndrome: cloning, sequence, and
structure of the human N- acetylgalactosamine 6-sulfatase
(GALNS) gene,” Genomics, vol. 22, no. 3, pp. 652–654, 1994.
[101] S. Tomatsu, A. M. Montan˜o, A. Ohashi et al., “Enzyme
replacement therapy in a murine model of Morquio A
syndrome,” Human Molecular Genetics, vol. 17, no. 6, pp.
815–824, 2008.
[102] S. Tomatsu, A. M.Montan˜o, H. Oikawa et al., “Mucopolysac-
charidosis type IVA (morquio a disease): clinical review and
current treatment: a special review,” Current Pharmaceutical
Biotechnology, vol. 12, no. 6, pp. 931–945, 2011.
[103] A. Rodrı´guez, A. J. Espejo, A. Herna´ndez et al., “Enzyme
replacement therapy for Morquio A: an active recombi-
nant N-acetylgalactosamine-6-sulfate sulfatase produced in
Biochemistry Research International 15
Escherichia coli BL21,” Journal of Industrial Microbiology and
Biotechnology, vol. 37, no. 11, pp. 1193–1201, 2010.
[104] A. Oshima, A. Tsuji, Y. Nagao, H. Sakuraba, and Y. Suzuki,
“Cloning, sequencing, and expression of cDNA for human
β-galactosidase,” Biochemical and Biophysical Research Com-
munications, vol. 157, no. 1, pp. 238–244, 1988.
[105] R. Santamaria, M. Blanco, A. Chabas, D. Grinberg, and
L. Vilageliu, “Identification of 14 novel GLB1 mutations,
including five deletions, in 19 patients with GM1 gangliosi-
dosis from South America,” Clinical Genetics, vol. 71, no. 3,
pp. 273–279, 2007.
[106] T. Takano and Y. Yamanouchi, “Assignment of human β-
galactosidase-A gene to 3p21.33 by fluorescence in situ
hybridization,” Human Genetics, vol. 92, no. 4, pp. 403–404,
1993.
[107] H. Morreau, N. J. Galjart, N. Gillemans, R. Willemsen, G. T.
J. Van Der Horst, and A. D’Azzo, “Alternative splicing of β-
galactosidase mRNA generates the classic lysosomal enzyme
and a β-galactosidase-related protein,” Journal of Biological
Chemistry, vol. 264, no. 34, pp. 20655–20663, 1989.
[108] E. Hinek, “Biological roles of the non-integrin
elastin/laminin receptor,” Biological Chemistry, vol. 377,
no. 7-8, pp. 471–480, 1996.
[109] S. Privitera, C. A. Prody, J. W. Callahan, and A. Hinek, “The
67-kDa enzymatically inactive alternatively spliced variant of
β- galactosidase is identical to the elastin/laminin-binding
protein,” Journal of Biological Chemistry, vol. 273, no. 11, pp.
6319–6326, 1998.
[110] A. C. M. M. Azevedo, I. V. Schwartz, L. Kalakun et
al., “Clinical and biochemical study of 28 patients with
mucopolysaccharides type VI,” Clinical Genetics, vol. 66, no.
3, pp. 208–213, 2004.
[111] L. Karageorgos, D. A. Brooks, A. Pollard et al., “Mutational
analysis of 105 mucopolysaccharidosis type VI patients,”
Human Mutation, vol. 28, no. 9, pp. 897–903, 2007.
[112] E. Fidzianska, T. Abramowicz, and B. Czartoryska, “Assign-
ment of the gene for human arylsulfatase B, ARSB, to
chromosome region 5p11 → 5qter,” Cytogenetics and Cell
Genetics, vol. 38, no. 2, pp. 150–151, 1984.
[113] D. Auclair, J. J. Hopwood, D. A. Brooks, J. F. Lemontt, and A.
C. Crawley, “Replacement therapy in Mucopolysaccharidosis
type VI: advantages of early onset of therapy,” Molecular
Genetics and Metabolism, vol. 78, no. 3, pp. 163–174, 2003.
[114] D. Auclair, J. Finnie, J. White et al., “Repeated intrathecal
injections of recombinant human 4-sulphatase remove dural
storage in mature mucopolysaccharidosis VI cats primed
with a short-course tolerisation regimen,” Molecular Genetics
and Metabolism, vol. 99, no. 2, pp. 132–141, 2010.
[115] D. Auclair, J. J. Hopwood, J. F. Lemontt, L. Chen,
and S. Byers, “Long-term intra-articular administration of
recombinant human N-acetylgalactosamine-4-sulfatase in
feline mucopolysaccharidosis VI,” Molecular Genetics and
Metabolism, vol. 91, no. 4, pp. 352–361, 2007.
[116] P. Harmatz, R. Giugliani, I. V. D. Schwartz et al., “Long-
term follow-up of endurance and safety outcomes during
enzyme replacement therapy for mucopolysaccharidosis VI:
final results of three clinical studies of recombinant human
N-acetylgalactosamine 4-sulfatase,” Molecular Genetics and
Metabolism, vol. 94, no. 4, pp. 469–475, 2008.
[117] S. Byers, M. Rothe, J. Lalic, R. Koldej, and D. S. Anson,
“Lentiviral-mediated correction of MPS VI cells and gene
transfer to joint tissues,” Molecular Genetics and Metabolism,
vol. 97, no. 2, pp. 102–108, 2009.
[118] G. Cotugno, P. Annunziata, A. Tessitore et al., “Long-term
amelioration of feline mucopolysaccharidosis VI after AAV-
mediated liver gene transfer,” Molecular Therapy, vol. 19, pp.
461–469, 2011.
[119] J. M. Shipley, M. Klinkenberg, B. M. Wu, D. R. Bachinsky,
J. H. Grubb, and W. S. Sly, “Mutational analysis of a patient
with mucopolysaccharidosis type VII, and identification of
pseudogenes,” American Journal of Human Genetics, vol. 52,
no. 3, pp. 517–526, 1993.
[120] W. S. Sly, B. A. Quinton, W. H. McAlister, and D. L. Rimoin,
“Beta glucuronidase deficiency: report of clinical, radiologic,
and biochemical features of a new mucopolysaccharidosis,”
The Journal of Pediatrics, vol. 82, no. 2, pp. 249–257, 1973.
[121] R. D. Miller, J. W. Hoﬀmann, P. P. Powell et al., “Cloning
and characterization of the human β-glucuronidase gene,”
Genomics, vol. 7, no. 2, pp. 280–283, 1990.
[122] F. Speleman, R. Vervoort, N. Van Roy, I. Liebaers, W. S.
Sly, and W. Lissens, “Localization by fluorescence in situ
hybridization of the human functional β-glucuronidase gene
(GUSB) to 7q11.21 → q11.22 and two pseudogenes to 5p13
and 5q13,” Cytogenetics and Cell Genetics, vol. 72, no. 1, pp.
53–55, 1996.
[123] J. M. Shipley, M. Klinkenberg, B. M. Wu, D. R. Bachinsky,
J. H. Grubb, and W. S. Sly, “Mutational analysis of a patient
with mucopolysaccharidosis type VII, and identification of
pseudogenes,” American Journal of Human Genetics, vol. 52,
no. 3, pp. 517–526, 1993.
[124] S. Tomatsu, A. M. Montano, V. C. Dung, J. H. Grubb,
and W. S. Sly, “Mutations and polymorphisms in GUSB
gene in mucopolysaccharidosis VII (sly syndrome),” Human
Mutation, vol. 30, no. 4, pp. 511–519, 2009.
[125] B. M. Wu, S. Tomatsu, S. Fukuda, K. Sukegawa, T. Orii, and
W. S. Sly, “Overexpression rescues the mutant phenotype
of L176F mutation causing β- glucuronidase deficiency
mucopolysaccharidosis in two Mennonite siblings,” Journal
of Biological Chemistry, vol. 269, no. 38, pp. 23681–23688,
1994.
[126] R. Vervoort, M. R. Islam, W. S. Sly et al., “Molecular analysis
of patients with β-glucuronidase deficiency presenting as
hydrops fetalis or as early mucopolysaccharidosis VII,”
American Journal of Human Genetics, vol. 58, no. 3, pp. 457–
471, 1996.
[127] I. Schwartz, L. R. Silva, S. Leistner et al., “Mucopolysaccha-
ridosis VII: clinical, biochemical and molecular investigation
of a Brazilian family,”Clinical Genetics, vol. 64, no. 2, pp. 172–
175, 2003.
[128] M. E. Haskins, G. D. Aguirre, P. F. Jezyk, E. H. Schuchman,
R. J. Desnick, and D. F. Patterson, “Mucopolysaccharido-
sis type VII (Sly syndrome): beta-glucuronidase-deficient
mucopolysaccharidosis in the dog,” American Journal of
Pathology, vol. 138, no. 6, pp. 1553–1555, 1991.
[129] D. C. S. Dombrowski, K. P. Carmichael, P. Wang, T. M.
O’Malley, M. E. Haskins, and U. Giger, “Mucopolysaccha-
ridosis type VII in a German shepherd dog,” Journal of the
American Veterinary Medical Association, vol. 224, no. 4, pp.
553–532, 2004.
[130] A. Bosch, E. Perret, N. Desmaris, and J. M. Heard, “Long-
term and significant correction of brain lesions in adult
mucopolysaccharidosis type VII mice using recombinant
AAV vectors,” Molecular Therapy, vol. 1, no. 1, pp. 63–70,
2000.
[131] A. Bosch, E. Perret, N. Desmaris, D. Trono, and J. M. Heard,
“Reversal of pathology in the entire brain of mucopolysac-
charidosis type VII mice after lentivirus-mediated gene
16 Biochemistry Research International
transfer,”HumanGene Therapy, vol. 11, no. 8, pp. 1139–1150,
2000.
[132] Y. Yamada, K. Kato, K. Sukegawa et al., “Treatment of MPS
VII (Sly disease) by allogeneic BMT in a female with homozy-
gous A619V mutation,” Bone Marrow Transplantation, vol.
21, no. 6, pp. 629–634, 1998.
[133] L. C. Ginsburg, D. T. DiFerrante, C. T. Caskey, and N. M.
DiFerrante, “Glucosamine-6-SO4 sulfatase deficiency: a new
mucopolysaccharidosis,” Clinical Research, vol. 25, p. 471A,
1977.
[134] L. C. Ginsberg, P. V. Donnelly, and D. T. Di Ferrante,
“N-acetylglucosamine-6-sulfate sulfatase in man: deficiency
of the enzyme in a new mucopolysaccharidosis,” Pediatric
Research, vol. 12, no. 7, pp. 805–809, 1978.
[135] N. Di Ferrante, “N-acetylglucosamine-6-sulfate sulfatase
deficiency reconsidered,” Science, vol. 210, no. 4468, p. 448,
1980.
[136] M. R. Natowicz, M. P. Short, Y. Wang et al., “Brief report:
clinical and biochemical manifestations of hyaluronidase
deficiency,” New England Journal of Medicine, vol. 335, no.
14, pp. 1029–1033, 1996.
[137] B. Triggs-Raine, T. J. Salo, H. Zhang, B. A. Wicklow, and
M. R. Natowicz, “Mutations in HYAL1, a member of a
tandemly distributed multigene family encoding disparate
hyaluronidase activities, cause a newly described lysoso-
mal disorder, mucopolysaccharidosis IX,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 96, no. 11, pp. 6296–6300, 1999.
[138] A. B. Csoka, G. I. Frost, and R. Stern, “The six hyaluronidase-
like genes in the human and mouse genomes,” Matrix
Biology, vol. 20, no. 8, pp. 499–508, 2001.
[139] L. Jadin, X. Wu, H. Ding et al., “Skeletal and hematolog-
ical anomalies in HYAL2-deficient mice: a second type of
mucopolysaccharidosis IX?” FASEB Journal, vol. 22, no. 12,
pp. 4316–4326, 2008.
[140] W. Krivit, “Allogeneic stem cell transplantation for the
treatment of lysosomal and peroxisomal metabolic diseases,”
Springer Seminars in Immunopathology, vol. 26, no. 1-2, pp.
119–132, 2004.
[141] R. Lachmann, “Treatments for lysosomal storage disorders,”
Biochemical Society Transactions, vol. 38, no. 6, pp. 1465–
1468, 2010.
[142] P. I. Dickson and A. H. Chen, “Intrathecal enzyme replace-
ment therapy for mucopolysaccharidosis I: translating suc-
cess in animal models to patients,” Current Pharmaceutical
Biotechnology, vol. 12, no. 6, pp. 946–955, 2011.
[143] A. Friso, R. Tomanin,M. Salvalaio, andM. Scarpa, “Genistein
reduces glycosaminoglycan levels in a mouse model of
mucopolysaccharidosis type II,” British Journal of Pharma-
cology, vol. 159, no. 5, pp. 1082–1091, 2010.
[144] A. L. K. Roberts, B. J. Thomas, A. S. Wilkinson, J. M. Fletcher,
and S. Byers, “Inhibition of glycosaminoglycan synthesis
using rhodamine B in a mouse model of mucopolysaccha-
ridosis type IIIA,” Pediatric Research, vol. 60, no. 3, pp. 309–
314, 2006.
[145] A. L. K. Roberts, M. H. Rees, S. Klebe, J. M. Fletcher,
and S. Byers, “Improvement in behaviour after substrate
deprivation therapy with rhodamine B in a mouse model of
MPS IIIA,” Molecular Genetics and Metabolism, vol. 92, no.
1-2, pp. 115–121, 2007.
[146] K. J. Langford-Smith, J. Mercer, J. Petty et al., “Heparin
cofactor II-thrombin complex and dermatan sulphate: chon-
droitin sulphate ratio are biomarkers of short- and long-term
treatment eﬀects in mucopolysaccharide diseases,” Journal of
Inherited Metabolic Disease, vol. 34, no. 2, pp. 499–508, 2011.
[147] C. M. Simonaro, M. D’Angelo, M. E. Haskins, and E. H.
Schuchman, “Joint and bone disease in mucopolysacchari-
doses VI and VII: identification of new therapeutic targets
and BioMarkers using animal models,” Pediatric Research,
vol. 57, no. 5 I, pp. 701–707, 2005.
[148] M. Fuller, J. N. Tucker, D. L. Lang et al., “Screening patients
referred to ametabolic clinic for lysosomal storage disorders,”
Journal of Medical Genetics, vol. 48, no. 6, pp. 422–425, 2011.
[149] M. Spada, S. Pagliardini, M. Yasuda et al., “High incidence
of later-onset Fabry disease revealed by newborn screening,”
American Journal of Human Genetics, vol. 79, no. 1, pp. 31–
40, 2006.
[150] H. Y. Lin, K. W. Chong, J. H. Hsu et al., “High incidence
of the cardiac variant of fabry disease revealed by newborn
screening in the Taiwan Chinese population,” Circulation,
vol. 2, no. 5, pp. 450–456, 2009.
[151] Y. H. Chien, S. C. Chiang, X. K. Zhang et al., “Early detection
of pompe disease by newborn screening is feasible: results
from the Taiwan screening program,” Pediatrics, vol. 122, no.
1, pp. e39–e45, 2008.
[152] P. K. Duﬀner, M. Caggana, J. J. Orsini et al., “Newborn
screening for Krabbe disease: the New York state model,”
Pediatric Neurology, vol. 40, no. 4, pp. 245–252, 2009.
